Table 1 The correlation between ARHGAP11A expression and clinicopathological characteristics in HCC patients
From: Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma
Clinicopathological variables | ARHGAP11A expression | P value | χ2 | |
|---|---|---|---|---|
High | Low | |||
Gender |  |  | P > 0.05 | 0.3 |
 Male | 33 | 29 |  |  |
 Female | 8 | 5 |  |  |
Age |  |  | P > 0.05 | 0.574 |
  < 45 y | 18 | 12 |  |  |
  ≥ 45 y | 23 | 22 |  |  |
Maximal tumor size |  |  | P < 0.05 | 4.467 |
  ≤ 5 cm | 19 | 24 |  |  |
  > 5 cm | 22 | 10 |  |  |
Tumor differentiation |  |  | P < 0.05 | 10.941 |
 I-II | 20 | 29 |  |  |
 III-IV | 21 | 5 |  |  |
Serum AFP |  |  | P > 0.05 | 0.313 |
  ≤ 400 (ng/ml) | 12 | 8 |  |  |
 > 400 (ng/ml) | 29 | 26 |  |  |
Metastasis |  |  | P < 0.05 | 3.969 |
 No | 30 | 31 |  |  |
 Yes | 11 | 3 |  |  |
TNM stage |  |  | P < 0.001 | 17.844 |
 I-II | 9 | 24 |  |  |
 III | 32 | 10 |  |  |